Teva Pharmaceutical Industries Limited [NYSE: TEVA] gained 3.61% or 0.37 points to close at $10.61 with a heavy trading volume of 10790503 shares. The company report on April 23, 2021 that Teva Announces Launch of its Generic Version of Canasa® (mesalamine) Suppositories To Treat Adults with Active Ulcerative Proctitis (ulcerative rectal colitis), in the United States.
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced the launch of its 1000 mg strength generic version of Casana®1 (mesalamine) suppository medicine used to treat adults with active ulcerative proctitis (ulcerative rectal colitis), in the U.S.
Ulcerative colitis (UC) results in inflammation or swelling of the rectum (the area between the colon and the anus). This inflammation may cause symptoms like bleeding, stomach pain, diarrhea, and urgency (a sudden urge to go to the bathroom). Ulcerative proctitis is common in people who have inflammatory bowel disease (IBD),2 and three times more common than Crohn disease (CD).3.
It opened the trading session at $10.28, the shares rose to $10.735 and dropped to $10.25, the range by which the price of stock traded the whole day. The daily chart for TEVA points out that the company has recorded 12.39% gains over the past six months. However, it is still -25.71% lower than its most recent low trading price.
If we look at the average trading volume of 8.95M shares, TEVA reached to a volume of 10790503 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Teva Pharmaceutical Industries Limited [TEVA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TEVA shares is $12.31 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TEVA stock is a recommendation set at 2.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
RBC Capital Mkts have made an estimate for Teva Pharmaceutical Industries Limited shares, keeping their opinion on the stock as Sector Perform, with their previous recommendation back on April 07, 2021. The new note on the price target was released on November 25, 2020, representing the official price target for Teva Pharmaceutical Industries Limited stock. Previously, the target price had yet another raise from $10 to $13, while Barclays kept a Equal Weight rating on TEVA stock.
The Average True Range (ATR) for Teva Pharmaceutical Industries Limited is set at 0.34, with the Price to Sales ratio for TEVA stock in the period of the last 12 months amounting to 0.70. The Price to Book ratio for the last quarter was 1.16, with the Price to Cash per share for the same quarter was set at 1.98. Price to Free Cash Flow for TEVA in the course of the last twelve months was 18.25 with Quick ratio for the last quarter at 0.70.
Trading performance analysis for TEVA stock
Teva Pharmaceutical Industries Limited [TEVA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.21. With this latest performance, TEVA shares dropped by -6.60% in over the last four-week period, additionally plugging by 12.39% over the last 6 months – not to mention a rise of 3.82% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TEVA stock in for the last two-week period is set at 45.08, with the RSI for the last a single of trading hit 47.07, and the three-weeks RSI is set at 45.55 for Teva Pharmaceutical Industries Limited [TEVA]. The present Moving Average for the last 50 days of trading for this stock 11.01, while it was recorded at 10.28 for the last single week of trading, and 10.52 for the last 200 days.
Teva Pharmaceutical Industries Limited [TEVA]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Teva Pharmaceutical Industries Limited [TEVA] shares currently have an operating margin of +18.36 and a Gross Margin at +46.38. Teva Pharmaceutical Industries Limited’s Net Margin is presently recorded at -23.95.
Return on Total Capital for TEVA is now 7.87, given the latest momentum, and Return on Invested Capital for the company is -11.37. Return on Equity for this stock declined to -34.11, with Return on Assets sitting at -7.60. When it comes to the capital structure of this company, Teva Pharmaceutical Industries Limited [TEVA] has a Total Debt to Total Equity ratio set at 263.30. Additionally, TEVA Total Debt to Total Capital is recorded at 72.47, with Total Debt to Total Assets ending up at 52.13. Long-Term Debt to Equity for the company is recorded at 231.50, with the Long-Term Debt to Total Capital now at 63.72.
Reflecting on the efficiency of the workforce at the company, Teva Pharmaceutical Industries Limited [TEVA] managed to generate an average of -$345,488 per employee. Receivables Turnover for the company is 3.34 with a Total Asset Turnover recorded at a value of 0.32.Teva Pharmaceutical Industries Limited’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 1.00.
Teva Pharmaceutical Industries Limited [TEVA]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Teva Pharmaceutical Industries Limited posted 0.76/share EPS, while the average EPS was predicted by analysts to be reported at 0.59/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 28.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TEVA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Teva Pharmaceutical Industries Limited go to 5.60%.
An analysis of insider ownership at Teva Pharmaceutical Industries Limited [TEVA]
There are presently around $6,067 million, or 52.40% of TEVA stock, in the hands of institutional investors. The top three institutional holders of TEVA stocks are: CAPITAL RESEARCH GLOBAL INVESTORS with ownership of 130,140,247, which is approximately 0.025% of the company’s market cap and around 0.79% of the total institutional ownership; CAPITAL WORLD INVESTORS, holding 52,879,377 shares of the stock with an approximate value of $561.05 million in TEVA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $453.99 million in TEVA stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Teva Pharmaceutical Industries Limited stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 186 institutional holders increased their position in Teva Pharmaceutical Industries Limited [NYSE:TEVA] by around 32,826,089 shares. Additionally, 206 investors decreased positions by around 28,836,179 shares, while 104 investors held positions by with 510,169,902 shares. The mentioned changes placed institutional holdings at 571,832,170 shares, according to the latest SEC report filing. TEVA stock had 59 new institutional investments in for a total of 7,418,598 shares, while 55 institutional investors sold positions of 3,305,856 shares during the same period.